Your browser is no longer supported. Please, upgrade your browser.
Settings
GWPH GW Pharmaceuticals plc daily Stock Chart
GWPH [NASD]
GW Pharmaceuticals plc
Index- P/E- EPS (ttm)-9.30 Insider Own0.04% Shs Outstand27.67M Perf Week-1.42%
Market Cap3.67B Forward P/E- EPS next Y-3.64 Insider Trans0.00% Shs Float2.04M Perf Month-9.44%
Income-245.30M PEG- EPS next Q-2.51 Inst Own81.30% Short Float90.66% Perf Quarter-12.03%
Sales16.20M P/S226.40 EPS this Y-84.20% Inst Trans0.48% Short Ratio4.54 Perf Half Y1.85%
Book/sh18.17 P/B7.29 EPS next Y53.00% ROA-46.10% Target Price167.29 Perf Year29.38%
Cash/sh16.07 P/C8.25 EPS next 5Y- ROE-52.70% 52W Range96.42 - 164.76 Perf YTD0.41%
Dividend- P/FCF- EPS past 5Y- ROI-46.80% 52W High-19.23% Beta2.79
Dividend %- Quick Ratio11.20 Sales past 5Y-24.30% Gross Margin67.00% 52W Low38.02% ATR5.11
Employees586 Current Ratio11.30 Sales Q/Q50.00% Oper. Margin- RSI (14)40.54 Volatility4.28% 3.60%
OptionableYes Debt/Eq0.01 EPS Q/Q-63.70% Profit Margin- Rel Volume0.32 Prev Close132.55
ShortableYes LT Debt/Eq0.01 EarningsAug 07 AMC Payout- Avg Volume406.20K Price133.08
Recom2.30 SMA20-2.63% SMA50-7.25% SMA2000.52% Volume91,216 Change0.40%
Aug-15-18Initiated Stifel Buy $181
Aug-08-18Reiterated Cantor Fitzgerald Overweight $235 → $211
Apr-19-18Reiterated Cantor Fitzgerald Overweight $192 → $205
Feb-06-18Reiterated Cantor Fitzgerald Buy $208 → $192
Dec-14-17Upgrade Goldman Neutral → Buy
Oct-06-17Resumed Goldman Neutral
Aug-17-17Initiated Evercore ISI Outperform $154
Aug-08-17Downgrade Maxim Group Buy → Hold
Apr-21-17Initiated Maxim Group Buy $135
Dec-05-16Reiterated Cantor Fitzgerald Buy $182 → $208
Oct-07-16Initiated Goldman Buy
Oct-04-16Resumed Leerink Partners Outperform $162
Sep-26-16Reiterated Cantor Fitzgerald Buy $165 → $182
Aug-26-16Upgrade Numis Sell → Hold
Aug-09-16Reiterated Cantor Fitzgerald Buy $181 → $165
Jun-03-16Initiated Cantor Fitzgerald Buy $181
Mar-03-16Initiated Numis Sell
Feb-18-16Reiterated Leerink Partners Outperform $129 → $100
Nov-30-15Initiated ROTH Capital Buy $130
Aug-13-15Initiated Morgan Stanley Overweight $150
Aug-15-18 11:29AM  Stifel Bullish On GW Pharma, Sees $1.5 Billion In Epidiolex Sales By 2023 Benzinga
Aug-13-18 05:40AM  GW Pharma Updates on Fiscal Q3 Results & Epidiolex Progress Investopedia
Aug-12-18 11:41AM  This U.S. Territory Is on the Verge of Legalizing Marijuana in a Unique Way Motley Fool
Aug-11-18 11:41AM  This Shocking Percentage of Americans Believe Marijuana Has at Least 1 Benefit Motley Fool
07:21AM  9 Ways to Invest in Marijuana Stocks Motley Fool
Aug-10-18 03:32PM  How to Profit Off the Marijuana Industry Motley Fool
Aug-09-18 12:41PM  Party City jumps, Roku soars, GW Pharma moves higher Yahoo Finance
11:26AM  Party City, Roku and GW Pharma are the Yahoo Finance charts of the day. Yahoo Finance Video
08:27AM  Micron, Ultra Clean Holdings, Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties, Molson Coors and Constellation Brands highlighted as Zacks Bull and Bear of the Day Zacks
Aug-08-18 08:36PM  New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year The Wall Street Journal
04:56PM  New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year The Wall Street Journal
03:13PM  Where to Find the Best Marijuana Stocks Zacks
11:01AM  Where to Find the Best Marijuana Stocks Zacks
Aug-07-18 08:14PM  Interested in Investing in Marijuana Stocks? Here's What You Ought to Know Motley Fool
05:30PM  GW Pharmaceuticals (GWPH) Stock Remains Flat as Loss Widens InvestorPlace
04:01PM  GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress GlobeNewswire
Aug-06-18 09:49AM  CBD Poses Both Opportunities And Obstacles For The Cannabis Industry Benzinga
09:47AM  GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards? Zacks
08:21AM  The Sneaky Reason Congress May Not Want to Legalize Marijuana Motley Fool
Aug-05-18 11:41AM  9 Ways Marijuana Has Made History This Year Motley Fool
07:21AM  Marijuana As a Cancer Treatment? This Study Offers Early Promise Motley Fool
Aug-03-18 08:00AM  Cannabis Companies Set to Explode, at any Moment ACCESSWIRE
Aug-01-18 11:06AM  Insys Therapeutics Is a Pretend Cannabis Stock TheStreet.com
Jul-24-18 09:00AM  Cannabinoids May Do More Than Manage Cancer Symptoms -- CFN Media GlobeNewswire
Jul-23-18 04:00PM  GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018 GlobeNewswire
08:53AM  CarMax, J.M. Smucker, Innovative Industrial Properties and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
Jul-22-18 11:41AM  Big Tobacco Makes Its First Investment in the Marijuana Industry Motley Fool
10:32AM  Why This Marijuana Stock Isn't the Bargain It Might Appear to Be Motley Fool
Jul-21-18 07:21AM  These 20 States Haven't Legalized Medical Marijuana, but That May Soon Change Motley Fool
Jul-20-18 09:00AM  Will Marijuana Stocks Bloom as US Moves Toward Legalization? Zacks
08:21AM  3 Very Popular Marijuana Stocks on My "Do Not Buy" List Motley Fool
Jul-19-18 04:10PM  Is Marijuana the Best Medicine for Epilepsy? Motley Fool
03:26PM  These Epilepsy Drugmakers Are About to Brawl Motley Fool
Jul-18-18 04:04PM  To make money on marijuana stocks, buy when the buzz is over MarketWatch
03:07PM  5 Big Biotech Stories to Watch TheStreet.com
09:21AM  3 Big-Name Marijuana Stocks With Plunging Profit Projections Motley Fool
Jul-17-18 10:30AM  3 Cannabis Stocks To Bet On For The Coming Cannabis Rush ACCESSWIRE
Jul-15-18 11:41AM  The 3 Biggest Problems With Marijuana's Schedule I Classification Motley Fool
Jul-14-18 11:41AM  Is Marijuana the Answer to the Opioid Epidemic? Some Seniors Believe So Motley Fool
07:18AM  Better Marijuana Stock: Aphria vs. GW Pharmaceuticals Motley Fool
Jul-13-18 05:34PM  Why Zogenix Inc. Shares Jumped 10% on Friday Motley Fool
11:34AM  Here's Why Marijuana Stock GW Pharmaceuticals Fell 13.3% in June Motley Fool
08:54AM  Zogenix's Epilepsy Candidate Successful in Phase III Study Zacks
Jul-12-18 10:10AM  Zogenix's seizure drug clears late-stage trial, shares soar Reuters
Jul-10-18 08:20AM  Today's Research Reports on Trending Tickers: Endo International and GW Pharmaceuticals ACCESSWIRE
Jul-08-18 11:41AM  The Rejection of This Marijuana Petition by the FDA Could Be a Bigger Deal Than You Realize Motley Fool
07:21AM  The Senate Appropriation Committee's Must-See Quote on Marijuana's Scheduling Motley Fool
Jul-07-18 11:41AM  This Country's Chief Medical Advisor Just Recommended Rescheduling Marijuana Motley Fool
Jul-04-18 09:21AM  The Best Marijuana Stocks in the Second Quarter Motley Fool
Jul-03-18 10:24AM  The DEA Is Rescheduling Epidiolex, But Not (Yet) Cannabis Or CBD Benzinga
10:20AM  U.S. Total CBD Market By Sector (in Millions) Benzinga
03:37AM  GW Pharma Receives Regulatory Go Ahead: Should You Buy? Investopedia
Jul-02-18 03:23PM  Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along InvestorPlace
Jul-01-18 11:41AM  Residents of This Red State Just Voted to Legalize Medical Marijuana Motley Fool
10:02AM  The 2 Most Wildly Overvalued Biotech Stocks Right Now Motley Fool
Jun-30-18 02:00PM  The FDA Finally Weighs In on Marijuana, and It's a Go Motley Fool
11:41AM  A Bill to Remove Marijuana From the Controlled Substances List Was Just Introduced Motley Fool
07:21AM  This FDA Approval Creates a Cannabis Conundrum in the U.S. Motley Fool
Jun-29-18 10:25AM  CBD Medicine Developments Provide a Really Solid Base for GWPH Stock InvestorPlace
08:10AM  Today's Research Reports on Trending Tickers: Canopy Growth and GW Pharmaceuticals ACCESSWIRE
05:00AM  Why the FDA Is High on a Marijuana Drug Bloomberg
Jun-28-18 07:18AM  6 Marijuana Stocks to Invest In for 1,000%+ Gains InvestorPlace
Jun-27-18 05:18PM  This Company Made the First FDA Approved, Marijuana Based Drug. Heres What It Wants to Do Next Fortune -5.79%
12:25PM  Heres the Reason that GWPH Stock Tumbled Despite Regulatory Victory InvestorPlace
09:41AM  Isodiol International Inc. Applauds the FDAs Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure GlobeNewswire
09:00AM  FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone TheStreet.com
08:06AM  Can the First Marijuana-Derived Drug Become a Blockbuster? Motley Fool
Jun-26-18 05:14PM  FDA's approval of new cannabis-based drug will pave the way for similar meds, says CEO CNBC
03:50PM  GW Pharmaceuticals' FDA Win Reinforces BofA's Bullish Thesis Benzinga
03:40PM  5 Hot Marijuana Stocks as Beer Companies Shop for an Acquisition InvestorPlace
03:24PM  FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight TheStreet.com
02:42PM  GW Pharma Trades Near Support After FDA Approval Investopedia
02:19PM  GW Pharma CEO on new cannabis-derived drug CNBC Videos
02:14PM  FDA greenlights first cannabis-derived drug CNBC Videos
01:10PM  420 Investor: Cannabis Drug Approval Creates 'Logic Issue' For The US Government Benzinga
11:20AM  Marijuana News: FDA Approves First-Ever Cannabis-Based Drug InvestorPlace
10:56AM  GW Pharmaceuticals, Spotify and Lennar are the Yahoo Finance charts of the day. Yahoo Finance Video
09:24AM  The first cannabis-derived drug was just approved in the U.S. MarketWatch
08:34AM  Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: GW Pharmaceuticals and PolarityTE ACCESSWIRE
06:33AM  Why GW Pharmaceuticals Stock Sank After Its Marijuana Drug Won a Historic FDA Approval Motley Fool
04:15AM  US Approves First Cannabis-Based Drug Investopedia
Jun-25-18 08:23PM  U.S. approves first marijuana plant-derived drug for epilepsy Reuters
05:08PM  FDA approves marijuana drug Yahoo Finance Video
05:02PM  The US FDA just approved the first use of a cannabinoid to treat forms of epilepsy Quartz
04:14PM  [$$] FDA Approves First Drug Derived From Marijuana Plant The Wall Street Journal
04:06PM  U.S. approves first marijuana plant-derived drug for epilepsy Reuters
04:04PM  U.S. approves first marijuana plant-derived drug for epilepsy Reuters
03:57PM  Cantor Fitzgerald Raises GW Pharma's Target To $235 Following Epidiolex Approval Benzinga
01:06PM  GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug Benzinga
12:57PM  GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution the First Plant-derived Cannabinoid Prescription Medicine GlobeNewswire
12:55PM  First Marijuana-Based Medicine Is Approved for Sale in U.S. Bloomberg
12:42PM  GW Pharma wins U.S. approval for marijuana-derived epilepsy drug Reuters
08:30AM  Harvest One Enters Pharmaceutical Market via Acquisition of PhytoTech Therapeutics in Israel CNW Group
Jun-24-18 07:21AM  Could This State Be the Next to Legalize Marijuana? Motley Fool
Jun-23-18 10:46PM  [$$] Cannabis-based epilepsy drug to be first to win US approval Financial Times
Jun-21-18 12:31PM  Key marijuana drug approval looms as cannabis goes mainstream Reuters
12:06PM  Key marijuana drug approval looms as cannabis goes mainstream Reuters
Jun-20-18 08:00AM  Today's Research Reports on Stocks to Watch: Canopy Growth and GW Pharmaceuticals ACCESSWIRE
Jun-19-18 02:42PM  Some fear changes to state laws as US weighs pot medicine Associated Press
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.